HOME >> MEDICINE >> NEWS
Drug aimed at Huntington's eases chorea, the disease's hallmark feature

A drug widely available in Europe and Canada but not the United States dramatically eases one of the most disabling symptoms of Huntingtons disease, involuntary writhing movements known as chorea, according to a study in the Feb. 14 issue of the journal Neurology.

The medication, tetrabenazine, is currently being reviewed by the U.S. Food and Drug Administration. If approved, the medication would be the first authorized by the agency expressly for the treatment of Huntingtons disease, which affects about 30,000 people in the United States.

In a randomized, controlled study conducted in 84 patients at 16 sites around the nation, doctors found that the medication cut down involuntary movement on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

Neuroleptic drugs like haloperidol (Haldol) are currently in widespread use in the United States to suppress chorea, but the effect of these drugs on chorea has never been studied in a systematic way, and they have a number of troublesome side effects, such as blunting of personality, loss of voluntary movement, and hindering balance. Our study showed that tetrabenazine, when appropriately dosed, can decrease chorea without causing those side effects, said Frederick J. Marshall, M.D., a neurologist at the University of Rochester Medical Center who led the study conducted by the Huntington Study Group. The study was funded by Prestwick Pharmaceuticals of Washington, D.C., the company that owns the rights to develop and sell the medication in the United States.

Tetrabenazine was originally developed in the 1950s to treat psychosis, but was quickly pushed aside by more effective medications. But doctors in the United Kingdom found it to be effective to treat the excessive involuntar
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
13-Feb-2006


Page: 1 2 3 4

Related medicine news :

1. Science of healthy foods subject of grant aimed at university students
2. Drug ads aimed at cancer patients difficult to read, make more appeals to effectiveness than safety
3. Cardiovascular flow disturbances study aimed at improving diagnosis and treatment
4. Endocrinologist-directed intervention aimed at primary care physicians improves diabetes care
5. New technology to speed up research into Huntingtons disease
6. Study identifies possible mechanism for brain damage in Huntingtons disease
7. Study identifies potential drug target for Huntingtons disease
8. Neural transplants provide persistent benefit in patients with Huntingtons disease
9. Rush designated Center of Excellence by Huntingtons Disease Society of America
10. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug aimed Huntington eases chorea the disease hallmark feature

(Date:4/21/2015)... Displays & Exhibits, Inc. a division of Absolute ... building industry, announced a management change of the retail ... in Tustin, California.“It is very important to have a ... in quality as offered by overseas trade show accessories ... Adduru is the new manager of Displays & Exhibits ...
(Date:4/21/2015)... 21, 2015 Henry Mayo Newhall Hospital, ... Care Exchange to automatically send continuation of care ... to further improve communication with clinics and other ambulatory ... Alert solution. , “Provider Alert will enable ... patient information they need to provide continuing care in ...
(Date:4/21/2015)... Texas (PRWEB) April 22, 2015 ... Review, H1 2015” provides comparative analysis on ... report strengthens R&D pipelines by identifying new ... best-in-class products. Complete report with TOC is ... The report also reviews key players involved ...
(Date:4/21/2015)... Texas (PRWEB) April 21, 2015 ... H1 2015” provides comparative analysis on the ... R&D pipelines by identifying new targets and ... Complete report with TOC is available @ ... also reviews key players involved in the ...
(Date:4/21/2015)... April 21, 2015 Information is the best ... Ryan, MD, FACP, empowers patients and their families with knowledge ... the Rumor and Cancer is the Answer" and new ... informative language to guide patients from diagnosis through treatment and ... active participants in their treatment, at home and in the ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... Summary Sepsis is a life-threatening complication arising ... to the infection damages its own tissues and organs. ... common among children <1 year of age, ... Clinic, 2014). Global estimates for the year 2013 showed ...
(Date:4/21/2015)... , April 21, 2015 InfuSystem Holdings, ... infusion pumps and related services for the healthcare industry ... Canada , announces today that it ... all of the assets of Ciscura Holding Company, Inc., ... GA , was a privately-held Southeastern regional provider ...
(Date:4/21/2015)...  A new, cutting edge prostate cancer test is ... revolutionize the way prostate cancer is diagnosed.  Dr. ... in Paris, France , performed the ... North Florida / South Georgia ... diagnosis and management to Greater Jacksonville ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 3InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 4Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 2Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 3
Cached News: